Radiotherapy for renal-cell carcinoma

详细信息    查看全文

• 作者：Prof Gert De Meerleer ; MD^a ; ^{gert.demeerleer@ugent.be" class="auth_mail} ; Vincent Khoo ; MD^c ; Bernard Escudier ; MD^d ; Steven Joniau ; PhD^f ; Alberto Bossi ; MD^e ; Piet Ost ; MD^a ; Alberto Briganti ; MD^g ; Valé ; rie Fonteyne ; MD^a ; Marco Van Vulpen ; MD^h ; Nicolaas Lumen ; PhD^b ; Martin Spahn ; MDⁱ ; Prof Marc Mareel ; MD^a
• 刊名：Lancet Oncology
• 出版年：April, 2014
• 年：2014
• 卷：15
• 期：4
• 页码：e170-e177
• 全文大小：256 K

文摘

| Figures/TablesFigures/Tables | ReferencesReferences

Summary

Renal-cell carcinoma is considered to be a radioresistant tumour, but this notion might be wrong. If given in a few (even single) fractions, but at a high fraction dose, stereotactic body radiotherapy becomes increasingly important in the management of renal-cell carcinoma, both in primary settings and in treatment of oligometastatic disease. There is an established biological rationale for the radiosensitivity of renal-cell carcinoma to stereotactic body radiotherapy based on the ceramide pathway, which is activated only when a high dose per fraction is given. Apart from the direct effect of stereotactic body radiotherapy on renal-cell carcinoma, stereotactic body radiotherapy can also induce an abscopal effect. This effect, caused by immunological processes, might be enhanced when targeted drugs and stereotactic body radiotherapy are combined. Therefore, rigorous, prospective randomised trials involving a multidisciplinary scientific panel are needed urgently.